Illumina (XSWX:ILMN) Stock Based Compensation: CHF209 Mil (TTM As of Mar. 2026)


XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF143.95
GF Value CHF105.51
! 7 Warning Signs
View Full Analysis

What is Illumina Stock Based Compensation?

Illumina XSWX:ILMN -0.79% 76 Stock Based Compensation is CHF209 Mil as of Mar. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review.

Illumina's Stock Based Compensation for the three months ended in Mar. 2026 was CHF47 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was CHF209 Mil.

Illumina Stock Based Compensation Related Terms

Illumina Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Illumina's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Stock Based Compensation Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 694.43 340.97 328.62 329.89 219.15

Illumina Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.50 56.11 55.73 50.21 47.24
XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF209 Mil.

What does a Stock Based Compensation of CHF209 Mil mean?
Illumina (XSWX:ILMN) has a Stock Based Compensation of CHF209 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Illumina and its competitors.
Is Illumina's Stock Based Compensation too high?
Illumina's current Stock Based Compensation is CHF209 Mil. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Stock Based Compensation compare to MTD and DGX?
Illumina's Stock Based Compensation of CHF209 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Illumina and its competitors. Illumina's current Stock Based Compensation is CHF209 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Stock Based Compensation of CHF209 Mil. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Stock Based Compensation is CHF209 Mil. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Stock Based Compensation is CHF209 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.

Key valuation signals for XSWX:ILMN:

  • Stock Based Compensation: CHF209 Mil
  • GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF143.95
Price
CHF105.51
GF Value